Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Domvanalimab · 2 trials · 2 indications
ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using investigator assessments.
PFS is defined as the time from the date of randomization until the first date of documented progressive disease (PD) or death from any cause, whichever occurs first, as measured by RECIST v1.1 using investigator assessments.
| Arm | Type | Description |
|---|---|---|
| Treatment Group A: Domvanalimab (DOM) + Zimberelimab (ZIM) + Platinum-based Chemotherapy | EXPERIMENTAL | Participants will receive DOM + ZIM + platinum-based chemotherapy (paclitaxel + carboplatin). |
| Treatment Group B: Zimberelimab (ZIM) + Platinum-based Chemotherapy | EXPERIMENTAL | Participants will receive ZIM + platinum-based chemotherapy (paclitaxel + carboplatin). |
| A1: Domvanalimab + Zimberelimab | EXPERIMENTAL | Domvanalimab and Zimberelimab, both administered by IV infusion |
| A2: Domvanalimab + Zimberelimab | EXPERIMENTAL | Domvanalimab and Zimberelimab, both administered by IV infusion |
| A3: Quemliclustat + Zimberelimab | EXPERIMENTAL | Quemliclustat and Zimberelimab, both administered by IV infusion |
| B1: Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Quemliclustat, zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B2: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B3: Domvanalimab + Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B4: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B5: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| C1: Quemliclustat + Zimberelimab + Docetaxel | EXPERIMENTAL | Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion |
| C2: Domvanalimab + Zimberelimab + Docetaxel | EXPERIMENTAL | Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion |
| Name | Type | Description |
|---|---|---|
| Domvanalimab | DRUG | Administered intravenously |
| Zimberelimab | DRUG | Administered intravenously |
| Paclitaxel | DRUG | Administered intravenously |
| Carboplatin | DRUG | Administered intravenously |
| Quemliclustat | DRUG | Administered as specified in the treatment arm |
| Docetaxel | DRUG | Administered as specified in the treatment arm |
| Platinum-Based Doublet | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: * Histologically or cytologically confirmed r/m squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies. * No prior systemic therapy for r/m HNSCC. Individuals who had disease progression or recurrence m...